共 19 条
[1]
Risk factors for antituberculous chemotherapy-induced hepatotoxicity in Japanese pediatric patients. Ohkawa K,Hashiguchi M,Ohno K,et al. Clinical Pharmacology and Therapeutics . 2002
[2]
Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Wang WM,Wu PC,Yuen MF,et al. Hepatology . 2000
[3]
Slow N-acetytransferase-2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Ohno M,Yamaguchi I,Yamamoto I,et al. International Journal of Tuberculosis and Lung Disease . 2000
[4]
Risk factors for hepatotoxicity induced by antituberculosis drugs. Devoto FM,Gonzalez C,Iannantuono R,et al. Acta Physiol Pharmacol Ther Latinoam . 1997
[5]
Safety of ofloxacin-based antituberculosis regimen for the treatment of tuberculosis in patients with underlying chronic disease: a preliminary report. Saigal S,Agarual RS,Nandeesh HP,et al. Journal of Gastroenterology . 2001
[6]
Isoniazid hepatotoxicity among drug users: the role of hepatitis C. Fernandez-Villar A,Sopena B,Vazquez R,et al. Clinical Infectious Diseases . 2003
[7]
Isoniazid-induced hepatic necrosis and steatosis in rabbits: absence of effect of gender. Serich TC,Adams SP,Zhou T,et al. Canadian Journal of Physiology and Pharmacology . 1997
[8]
Antituberculosis drug-induced hepatotoxicity: the role of hepatitis C virus and the human immunodeficiency virus. Ungo JR,Jones D,Ashkin D,et al. American Journal of Respiratory and Critical Care Medicine . 1998
[9]
Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 ’null’ mutation. Roy B,Choudhury A,Kandy S,et al. Journal of Gastroenterology . 2001
[10]
Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Jasmer RM,Saukkonen JJ,Blumberg HM. Annals of Internal Medicine . 2002